InvestorsHub Logo
Followers 333
Posts 30995
Boards Moderated 3
Alias Born 07/07/2006

Re: Fress post# 1732

Friday, 03/13/2020 2:07:13 PM

Friday, March 13, 2020 2:07:13 PM

Post# of 5070
Interesting ... read this on yahoo finance and grabbed some BCRX

Proof of Concept Data is coming this weekend this could double or triple in a blink of an eye. Making money most biotechs are not 90% owned by institutions 120 Million in cash FDA approved products Other approvals coming in Japan soon. Corona virus news will send this into another orbit look at the Presentation from Last week there in the clinic already and have received tens of million in government funding.
From March 10-2020 Companies Presentation: Page 15

COVID-19 Antiviral Status Update: Galidesivir (BCX4430)

$82 M of program support to date:
1 Warren, T. K. et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402-405, doi:10.1038/nature13027 (2014)

• Recurring global health crises from emerging viral infections highlight the
critical need for broad spectrum antivirals in government stockpiles to
protect public health

• Galidesivir has shown activity against >20 RNA viruses in 9 different
families, including coronaviruses1
• Activity against COVID-19 coronavirus

• Galidesivir was safe and generally well tolerated in two Phase 1 trials
• Development has progressed to clinical trial in Yellow Fever

BioCryst working with the U.S. government to explore:
• In vitro testing against COVID-19 virus
• Advancing to clinical trial in COVID-19
• Increasing drug supply

$BCRX
http://ir.biocryst.com/static-files/bc230cc6-b634-496d-862d-80a665f5fcec

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BCRX News